Prostate cancer (PrCa) is a significant public health problem. In the European Union, approximately 200 000 men are diagnosed annually with the disease. There are 35 515 cases ([@bib6]) per year in the United Kingdom and 10 239 deaths ([@bib7]). It is now the commonest male non-cutaneous cancer diagnosed in the United Kingdom; the lifetime risk of being diagnosed with PrCa is 1 in 10 ([@bib6]). Although the increase in population screening is leading to an increase in diagnosis, many men will not develop aggressive disease. However, it is recognised that some PrCa cases have a particularly poor prognosis. Although there are some histological and stage predictors of prognosis ([@bib17]), until recently, none of them have been related to inherited factors.

Multiple aetiologies have been proposed to contribute to the development of PrCa. There is strong evidence that inherited genetic factors are important and exhibit significant familial aggregation in some men, particularly when affected at a young age ([@bib31]; [@bib10]). There is a recognised association of breast cancer with PrCa in families ([@bib23]; [@bib2]; [@bib29]). Male relatives in breast cancer families in Iceland have a 2--3-fold risk of PrCa ([@bib21]). The breast cancer predisposition genes *BRCA1* and *BRCA2* have been reported to increase the risk of PrCa by three-fold and seven-fold, respectively, in male mutation carriers ascertained through a family history of breast cancer ([@bib13]; [@bib22]; [@bib5]). Analyses of PrCa relative risks (RR) in male mutation carriers in breast cancer families from the Breast Cancer Linkage Consortium showed an RR of 4.65 (95% CI: 3.48--6.22) of PrCa in male *BRCA2* mutation carriers (the RR is 7.33 below the age of 65 years) and of 1.07 (0.75--1.54) in *BRCA1* carriers (with an RR of 1.82 (1.01--3.29) for men under 65 years of age) ([@bib24], [@bib25]). The estimated cumulative incidence of PrCa by the age of 70 years is 7.5--33%. Recent studies have suggested that the risk of PrCa in *BRCA2* mutation carriers may be as high as an RR of 23-fold at age 60 years ([@bib11]). Studies from Iceland have reported that germline mutations in *BRCA2* may be involved not only in susceptibility to PrCa but also in the aggressiveness of the disease ([@bib21]; [@bib28]). However, these individuals all carried a common founder mutation (999del5 in *BRCA2*). [@bib20]) have reported that PrCa survival in *BRCA2* mutation carriers is much shorter (median survival from diagnosis was 4 years) when compared with *BRCA1* carriers\' survival (median survival from diagnosis was 8 years). In PrCa, in which the *BRCA2* germline mutation status was unknown, allele loss at the *BRCA2* locus has been shown to be a prognostic factor for survival on univariate analysis ([@bib9]), and loss of the wild-type allele would imply a tumour suppressor mechanism in predisposition to this disease in *BRCA2* mutation carriers, but it is not known whether this is a surrogate for high grade or is due to mutation *per se* ([@bib18]; [@bib30]).

A *BRCA2* genomic screening study has previously been undertaken by ourselves, and six potentially pathogenic germline *BRCA2* mutations were found in a set of 263 PrCa patients diagnosed at ⩽55 years (2.3%) ([@bib11]). In this study we report clinical follow-up data and the results of loss of heterozygosity (LOH) analyses on PrCa tumours from the mutation carriers in this report.

We then studied a second validation data set of men with germline mutations in the *BRCA2* gene from a cancer genetics clinic and assessed their survival to confirm our results in a different UK data set of male *BRCA2* mutation carriers with PrCa.

Materials and methods
=====================

Patient recruitment and survival analyses
-----------------------------------------

Two groups of men with PrCa were studied.

1\) *A series of men with PrCa from the UK Genetic Prostate Cancer Study (UKGPCS):*

Patient recruitment was conducted as reported in a previous article ([@bib12]). The coding region of *BRCA2* was analysed from blood DNA from 263 PrCa patients diagnosed at ⩽55 years and germline mutations in *BRCA2* were found in 6 men (2.3%) ([@bib11]). The control group consisted of men from a systematic series of prostate cancer patients, age and stage matched from our prostate cancer clinic (1587 cases). The majority of patients had clinically presenting (non-screen detected) disease at diagnosis. Clinical data were collected on survival/date of last follow-up for both deleterious *BRCA2* mutation carriers and controls. Supplementary Table 1 shows the demographic and clinical characteristics of prostate cancer in this group of patients, for both the cases and controls.

2\) *Men with PrCa who also harbour a germline BRCA2 mutation from a clinical series:*

Men attending a cancer genetics clinic in Manchester, who were found on clinical genetic testing to harbour *BRCA2* mutations, were reviewed from the Access clinical database and their date of death or last follow-up was ascertained from the cancer registry or from their clinical notes.

Written informed consent was obtained from individuals in this study (ethics number 06/MRE02/4).

Overall survival was measured from date of diagnosis to date of death or last follow-up. Kaplan--Meier survival analyses were undertaken with patients censored at date of last follow-up. The overall survival of those with and without germline mutations in *BRCA2* in group 1 was compared using the log-rank test. The overall survival for those in group 2 was also calculated separately and in combination with group 1. The effect of other factors that could affect survival was analysed using Cox regression. The factors investigated were stage at diagnosis, incidental PSA detection, Gleason score, grade, whether they had a prostatectomy, PSA at diagnosis and age.

DNA extraction and LOH studies
------------------------------

Germline DNA was obtained from peripheral blood samples and extracted as reported in previous articles ([@bib8]). Tumour DNA was obtained from microdissected formalin-fixed paraffin-embedded (FFPE) blocks and extracted as reported in previous articles ([@bib9]). Normal tissue DNA was also obtained in the same way.

Four microsatellite markers, D13S260, D13S171, D13S267 and D13S1493 within and flanking the *BRCA2* gene, were typed on five tumours from those men in group 1 using an ABI (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA, USA) 377 Genetic Analyser. The 'peak height\' of the alleles was used to determine the ratio of allelic loss compared with either genomic DNA or adjacent normal tissue from paraffin blocks. Percentage allele loss for informative markers (minimum of two) was averaged for each patient.

To determine which allele was lost in the microsatellite LOH results, a sequencing method was used as described in [@bib3]. We used Applied Biosystems dRhodamine chemistry on a 377 Genetic Analyser ([@bib11]). An average value for the loss was estimated by examining a number of electropherogram peak height signals in the area of the mutation.

Results
=======

Survival analysis
-----------------

The median overall survival of all *BRCA2* mutation carriers was significantly shorter at 4.8 years compared with that of non-carriers at 8.5 years; log rank *P*=0.003 (hazard ratio 2.14 (95% CI: 1.28--3.56); see [Figure 1)](#fig1){ref-type="fig"}. When analysed by method of ascertainment (see methods), the median survival of the six *BRCA2* carriers in group 1 was significantly shorter at 3.6 years (*P*=0.002; hazard ratio 3.36 (95% CI: 1.50--7.50)), when compared with that of non-carriers. In group 2, the 15 men with germline *BRCA2* mutations and PrCa had a median survival of only 5.0 years.

The mutations in *BRCA2* in the men with PrCa are listed in [Table 1](#tbl1){ref-type="table"}.

[Table 2](#tbl2){ref-type="table"} shows the univariate results. This shows that the following factors are associated with a poorer overall survival: germline *BRCA2* mutation status, tumour (T), nodal (N) and metastasis (M) stage, tumour detected clinically rather than by PSA screening, higher Gleason score, treatment that did not involve prostatectomy, PSA at diagnosis of ⩾25 ng ml^−1^ and age \>55 years at diagnosis. In a multivariate analysis, which is shown in [Table 3](#tbl3){ref-type="table"}, germline *BRCA2* mutation status, T and nodal (N) tumour stage, higher grade, treatment that did not involve prostatectomy, PSA at diagnosis of ⩾25 ng ml^−1^ and higher age at diagnosis remained independent prognostic factors.

Loss of heterozygosity (LOH) results
------------------------------------

The DNA from microdissected FFPE tumour tissue was available from 5 of 6 germline *BRCA2* carriers. All five showed LOH (see [Table 4](#tbl4){ref-type="table"}). A representative microsatellite trace is shown in [Figure 2](#fig2){ref-type="fig"}.

To estimate which allele was lost, a sequencing method was adopted. Of the five tumour samples sequenced, it was observed that patient F had lost the mutant allele, whereas patients A, D and E lost the wild-type allele. The tumour from patient B had lost the mutant allele at a low level (approx 10% [Table 4)](#tbl4){ref-type="table"}. Representative sequence traces are shown in [Figure 3](#fig3){ref-type="fig"}.

Discussion
==========

We have shown that men with PrCa, who also harbour a deleterious germline mutation in the *BRCA2* gene, have a poorer overall survival. This has been shown in a small sample of men who were diagnosed at ⩽55 years with PrCa, compared with those diagnosed at a similarly young age, but who did not harbour a germline mutation as determined by coding sequence analysis from a previous study, and also men from a systematic series of prostate cancer cases in one centre: group 1 ([@bib11]). We have validated this in a separate data set of men who have had PrCa at any age and who have been found to have a germline mutation in *BRCA2* by a clinical genetic testing service, in which genetic testing was offered as part of genetic counselling of families with mutations: group 2. These are usually men within breast cancer families in which women have initially been tested to determine the cause of familial breast cancer clustering within the family. Again, they have a poorer prognosis than men who do not harbour a germline *BRCA2* mutation.

It has been shown that local extent or T stage, N stage and presence or not of M stage and higher PSA at presentation are all predictors of poorer survival ([@bib17]). It was therefore very important to determine whether the poorer survival associated with the presence of a germline *BRCA2* mutation was independent. The multivariate analysis confirms that the presence of a germline *BRCA2* mutation is a marker of poorer overall survival *per se.*

This has implications for the detection and management of men with PrCa who are found to harbour germline mutations in the *BRCA2* gene, as their poorer survival would be a contraindication for active surveillance. It is not yet known whether these men should have a particular modality of treatment (e.g., surgery rather than radiation), as the sample sizes in this paper are too small and treatment data are incomplete in these data sets to be able to determine this.

Before 2008, the only data available on survival in men with PrCa who harbour germline mutations in *BRCA2* were from Iceland, where there is a founder mutation ([@bib26]; [@bib21]; [@bib28]). [@bib28] found that PrCa carriers with the *BRCA2* 999del5 mutation had a lower mean age at diagnosis, more advanced PrCa as assessed by stage and grade, and a shorter median survival time compared with non-carriers. Their study showed a median survival time for carriers (30) of 2.1 years, which was significantly shorter than the 12.4 years for non-carriers (497). The survival time of the Icelandic carriers is much shorter than that reported for our early-onset group 1 carriers of 4 years. One factor to be noted in the [@bib28] study is that all of the 527 PrCa patients were related to breast cancer patients, 28% of whom were first-degree relatives. Of the 527 patients, 30 were determined to be 999del5 carriers. It is therefore possible that the poorer prognosis that was reported could have pertained only to this specific mutation type. This result, and its potential specificity by virtue of mutation and population, has been discussed further by [@bib4]. In contrast, we have shown that in the UK population, men with a variety of other mutations in *BRCA2*, are likely to have a similarly poorer survival, and therefore the poorer survival is likely to be related to different deleterious mutations in the *BRCA2* gene.

We found LOH in the five available PrCa tumours from men in group 1.Three of the five tumours had lost the wild-type allele. This is consistent with a tumour suppressor model and indicative of a causal relationship between *BRCA2* germline mutations and predisposition to PrCa in these individuals. Loss of the mutant allele was also observed. The implication is that for disease causation, maybe a gene dosage effect is important.

[@bib27] have recently proposed a model of 'conditional haploinsufficiency\', whereby defects in genes such as *BRCA1* or *BRCA2* can disrupt the regulation of other important genome integrity monitoring genes such as *ATM*. In this hypothesis, the local effects of these predisposing genes, by virtue of perhaps increased DNA double-strand breaks, would ultimately cause ATM protein inactivation as the cells progressed to malignancy. Although this haploinsufficiency mechanism has only been investigated in breast cancer, it may have implications for the development of PrCa in the carriers that we studied, and could explain why we saw loss of mutant alleles in comparison with the classical loss of wild type.

There is very scant literature on the 'classical\' loss of wild-type alleles from PrCa patients who are *BRCA2* carriers. [@bib15] and [@bib14] have reported LOH in PrCa patients. [@bib15] investigated five high-risk breast cancer families and found seven men with PrCa, six of whom had LOH at the *BRCA2* locus. [@bib14] studied a breast/prostate family (three breast cancer, five PrCa) that was found to have a deleterious *BRCA2* mutation (6051delA). Of the four brothers with PrCa, two had LOH (loss of WT) and two retained heterozygosity.

[@bib30] reported on the screening of a large series of kConFab Australian *BRCA2* breast cancer families. There were many men with PrCa in these families; however, 20 were confirmed to be *BRCA2* carriers, and 14 of them had tumours that were available for analysis by multiplex ligation-dependent probe amplification (MLPA). This technique is able to assay the entire *BRCA2* gene for loss of promoter and coding regions. Of the 14 *BRCA2* carriers, 10 showed loss of heterozygosity by the MLPA method. The set comprised six men with a known family history of PrCa and all the six showed LOH at *BRCA2*. The conclusion was that the wild-type allele was most often lost, but for the four cases that showed no LOH, epigenetic and haploinsufficiency models were postulated as possible mechanisms. This allele determination was assessed by a sequencing technique that is similar to the one we used. [@bib30] reported comprehensive clinical data on their carriers and it is noteworthy that all 10 PrCa cases presented with high Gleason scores of 9. This is a finding that is similar to the high-grade presentation of the men in our study group 1. The risk estimates of 3.5-fold for PrCa, as reported by [@bib30], are lower than the RR reported by us in 2003 ([@bib11]).

In 2008, [@bib20] reported data on a panel of PrCa patients with *BRCA1* and *BRCA2* germline mutations identified from breast cancer families. For the combined group of known and inferred carriers, the median survival for 183 *BRCA2* patients was 4.0 years *vs* 8.0 years for the 119 men in the *BRCA1* group. When only known carriers were analysed, the results were 5.0 years (67 *BRCA2* known carriers) and 15.0 years (37 *BRCA1* known carriers). Although there is a difference in the survival of *BRCA1* patients, which is discussed by the authors, the poorer survival of *BRCA2*-related patients is not in dispute. Use of either survival measure, 4 or 5 years, illustrates that the median survival of the patients studied is very similar to that observed in our study of 4.8 years.

It is not yet known whether earlier detection of PrCa in men with germline mutations in *BRCA2* will result in a better outcome and whether PSA screening is suitable for such a population. The IMPACT study ([I]{.ul}dentification of [M]{.ul}en with a genetic predisposition to [P]{.ul}rost[A]{.ul}te [C]{.ul}ancer: [T]{.ul}argeted screening in *BRCA1* and *BRCA2* mutation carriers and controls) has been developed to investigate the role of targeted PrCa screening in male *BRCA1* and *BRCA2* gene mutation carriers using an annual PSA screen ([@bib19]). Early data have suggested that men will uptake screening and that PrCa was twice as likely in *BRCA1/2* mutation carriers ([@bib16]).

Our data have shown that the observation in Iceland, which shows that men who carry the Icelandic founder mutation in the *BRCA2* gene who also develop PrCa have a poorer survival, is not restricted to this mutation and we have shown that this is due to the presence of a deleterious mutation within the *BRCA2* gene *per se.* There is some dispute about the precise frequency of germline *BRCA2* mutation in men with PrCa. This is reported to be about 1% in men aged ⩽55 years in a US series ([@bib1]), but this may be equivalent to 65--68 years at *clinical* diagnosis, as the prevalence of PSA screen-detected disease is higher in the United States. This is likely to be the case, as in this US series, 67.3% of men had a PSA of \<10. We have found that 2.3% of men diagnosed with clinically presenting disease (non-PSA detected) have a germline *BRCA2* mutation ([@bib11]). Even if the incidence of a germline mutation in men with young-onset (defined as ⩽55 years at diagnosis) PrCa was as low as 2%, the finding of a *BRCA2* mutation would be an indication to avoid active surveillance in these patients, as they have a more aggressive disease outcome.
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![Kaplan--Meier survival estimates of 21 *BRCA2* mutation carriers.](6605822f1){#fig1}

![Example of LOH seen with D13S1493 in two patients -- A and D.](6605822f2){#fig2}

![Examples of allele loss in patients A, D and F. Arrows show the position of a representative peak for signal analysis.](6605822f3){#fig3}

###### List of germline mutations in *BRCA2* men with prostate cancer from group 1 (diagnosed at age 55 years or under) and group 2

  **Patient ID**       **Age at diagnosis (Years)**   **BRCA2 mutation (nt) U43746**   **BRCA2 mutation (nt) NM_000059.1**   **Codon U43746**             **Codon NM_000059.1 with HGVS nomenclature**
  -------------------- ------------------------------ -------------------------------- ------------------------------------- ---------------------------- ----------------------------------------------
  Group 1 patient A    44                             8205-1g\>c (IVS17-1g\>c)         7977-1g\>c                            IVS17-1 g\>c (splice site)   7977-1g\>c (splice site)
  Group 1 patient B    47                             7084delAAAAG                     6856delAAAAG                          Stop 2291                    Arg2287LeufsX4
  Group 1 patient C    48                             2558insA or 2558dupA             2330insA or 2330dupA                  Stop 787                     Asp777GlufsX11
  Group 1 patient D    52                             8525delC                         8297delC                              Stop 2776                    Thr2766AsnfsX11
  Group 1 patient E    52                             6714delACAA^\*^                  6486delACAA                           Stop 2166                    Lys2162AsnfsX5
  Group 1 patient F    53                             7771insA or 7771dupA             7543insA or 7543dupA                  Stop 2537                    Thr2515AsnfsX24
                                                                                                                                                           
  Group 2 patient 1    66                             6174delT                         5946delT                              Stop 2003                    Ser1982ArgfsX22
  Group 2 Patient 2    66                             5910C\>G                         5682C\>G                              Y1894X (Tyr to Stop)         Tyr1894X
  Group 2 patient 3    79                             9610C\>T                         9382C\>T                              R3128X (Arg to Stop)         Arg3128X
  Group 2 patient 4    74                             860-1g\>a                        632-1g\>a                             IVS7-1g\>a (splice site)     632-1g\>a (splice site)
  Group 2 patient 5    46                             6503delTT (+) 10204A\>T          6275-6276delTT (+) 9976A\>T           Stop 2098 + K3326X           Leu2092ProfsX7 + Lys3326X
  Group 2 patient 6    77                             2157delG                         1929delG                              Stop 659                     Arg645GluX15
  Group 2 patient 7    74                             6503delTT (+) 10204A\>T          6275-6276delTT (+) 9976A\>T           Stop 2098 + K3326X           Leu2092ProfsX7 + Lys3326X
  Group 2 patient 8    57                             6819delTG                        6591delTG                             Stop 2201                    Glu2198AsnfsX4
  Group 2 patient 9    59                             3036delACAA                      2808delACAA                           Stop 959                     Ala938ProfsX21
  Group 2 patient 10   72                             6137C\>A                         5909C\>A                              S1970X                       Ser1970X
  Group 2 patient 11   62                             2117delC                         1889delC                              Stop 643                     Thr630AsnfsX14
  Group 2 patient 12   74                             del exons 14-16                  94189-?\_97257+?del                   Del exons 14-16              del exons14_16
  Group 2 patient 13   66                             del exons 14-16                  94189-?\_97257+?del                   Del exons 14-16              del exons14_16
  Group 2 patient 14   56                             5950delCT                        5722delCT                             Stop 1909                    Leu1908ArgfsX2
  Group 2 patient 15   73                             2157delG                         1929delG                              Stop 659                     Arg645GluX15

###### Univariate analysis of overall survival

  **Factor**                  **Group**   **Number of patients**   **Hazard ratio (95% CI)**   ***P*-value**
  -------------------------- ----------- ------------------------ --------------------------- ---------------
  *BRCA2* mutation carrier       No                1587                      1.00                  0.003
                                 Yes                21                 2.14 (1.28--3.56)              
  Clinical T stage               T1                165                       1.00                 \<0.001
                                 T2                409                 1.23 (0.92--1.65)              
                                 T3                510                 1.88 (1.43--2.49)              
                                 T4                152                 3.87 (2.83--5.28)              
                                 TX                325                 4.80 (3.63--6.36)              
  N stage                        N0                882                       1.00                 \<0.001
                                N1--3              165                 3.04 (2.46--3.76)              
                                 NX                514                 3.32 (2.88--3.84)              
  M stage                        M0                1008                      1.00                 \<0.001
                                 M1                456                 4.38 (3.80--5.05)              
                                 MX                 86                 1.61 (1.21--2.15)              
  Incidental PSA detection       Yes               127                       1.00                 \<0.001
                                 No                1362                2.41 (1.74--3.34)              
  Gleason score                  ⩽7                686                       1.00                 \<0.001
                                 \>7               181                 2.30 (1.85--2.85)              
  Grade                           1                200                       1.00                 \<0.001
                                  2                857                 1.77 (1.38--2.27)              
                                  3                330                 4.02 (3.09--5.23)              
  Prostatectomy                  Yes                82                       1.00                 \<0.001
                                 No                1423                4.70 (2.82--7.83)              
  PSA at diagnosis              \<25               498                       1.00                 \<0.001
                                 ⩾25               487                 2.19 (1.83--2.63)              
  Age group                      ⩽55               119                       1.00                  0.02
                                \>55               1474                1.40 (1.05--1.87)              
  Age                         Per year             1593                1.05 (1.04--1.06)          \<0.001

Abbreviations: CI=confidence interval; M=metastasis; N=nodal; PSA=prostate-specific antigen; T=tumour.

###### Multivariate analysis of overall survival (significant factors only)

  **Factor**                  **Group**    **Number of patients**   **Number of events**   **Hazard ratio (95%CI)**   ***P*-value**
  -------------------------- ------------ ------------------------ ---------------------- -------------------------- ---------------
  *BRCA2* mutation carrier        No                506                     218                       1                   0.002
                                 Yes                 3                       3                7.54 (2.11--26.98)             
  Clinical T stage                T1                 51                      16                       1                   0.002
                                  T2                158                      49               0.99 (0.56--1.75)              
                                  T3                202                      87               1.19 (0.68--2.05)              
                                  T4                 50                      34               1.87 (1.00--3.48)              
                                  TX                 48                      35               2.34 (1.24--4.40)              
  N stage                         N0                344                     111                       1                  \<0.001
                                N1--3                66                      40               2.01 (1.36--2.98)              
                                  NX                 99                      70               3.72 (2.65--5.23)              
  Grade                           1                  33                      7                        1                  \<0.001
                                  2                 376                     152               2.24 (1.03--4.88)              
                                  3                 100                      62               3.94 (1.78--8.73)              
  Prostatectomy                  Yes                 31                      4                        1                   0.044
                                  No                478                     217               2.84 (1.03--7.85)              
  PSA at Diagnosis               \<25               282                      96                       1                   0.027
                                 ⩾25                227                     125               1.39 (1.04--1.86)              
  Age                         Per year\>            509                     221               1.02 (1.00--1.04)           0.026

Abbreviations: CI=confidence interval; N=nodal; PSA=prostate-specific antigen; T=tumour.

###### LOH frequencies observed for the five patients from group 1

  **Patient ID**   **Number of informative markers**   **LOH (%)**[a](#t4-fn2){ref-type="fn"}    **Allele lost**[b](#t4-fn3){ref-type="fn"}
  ---------------- ----------------------------------- ---------------------------------------- --------------------------------------------
  A                3                                   77                                                            WT
  B                4                                   87                                                           MUT
  D                2                                   97                                                            WT
  E                4                                   77                                                            WT
  F                3                                   81                                                           MUT

Abbreviations: MUT=mutant; LOH=loss of heterozygosity; WT=wildtype.

LOH (%) by microsatellite analysis (average).

Allele loss estimation by sequencing.

[^1]: For list of 'The UK Genetic Prostate Cancer Study\' Collaborators, see online supplementary information
